secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2026-06-08T11:05:29+00:00
Accession:  0001493152-26-027621
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix secures second GPO agreement for TONMYA, expanding commercial coverage to ~52M lives
--------------------------------------------------------------------------------

- Second GPO agreement effective June 1, 2026 adds ~17M US commercial lives (~10% of total).
- Total commercial coverage now ~52M lives (~29% of US commercial lives); first GPO covered ~35M from May 1.
- TONMYA covered under Medicaid in most states (~75M beneficiaries); Medicare discussions ongoing.
- TONMYA (cyclobenzaprine HCl sublingual tablets) approved by FDA Aug 2025 as first new fibromyalgia treatment in over 15 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226027621/0001493152-26-027621-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000149315226027621/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-027621

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer